{"pmid":32415727,"title":"COVID-19 knowledge prevents biologics discontinuation: data from an Italian multi-center survey during RED-ZONE declaration.","text":["COVID-19 knowledge prevents biologics discontinuation: data from an Italian multi-center survey during RED-ZONE declaration.","BACKGROUND: SARS-CoV-2 become pandemics and there is still a dearth of data about its the potentially among dermatological patients under biologics. OBJECTIVE: To assess health literacy, disease knowledge, treatment dissatisfaction and biologics attitudes toward COVID-19. METHODS: We performed a cross-sectional, questionnaire-based survey on 98/105 consecutive dermatological patients treated with biologics - 51 suffering from plaque psoriasis, 22 from atopic dermatitis, and 25 from hidradenitis suppurativa. An ad hoc, validated questionnaire has 44 items investigating the following domains: knowledge of COVID-19 related to i) epidemiology, ii) pathogenesis, iii) clinical symptoms, iv) preventive measures and v) attitudes. Patients data and questionnaires were collected. RESULTS: Despite only 8.1% thought that biologics may increase the risk of COVID-19, 18.4% and 21.4% of the patients were evaluating the possibility to discontinue or modify the dosage of the current biologic therapy, respectively. Globally, male patients(p=0.001) with higher scholarity level(p=0.005) displayed higher knowledge of COVID-19. Patients with lower DLQI(p=0.006), longer disease duration(p=0.051) and lower scholarity(p=0.007) have thought to discontinue/modify autonomously their biologic therapy.At the multivariate logistic regression, only the knowledge of epidemiology and preventive measures resulted independent predictors of continuation versus discontinuation and modification versus no modification, respectively. CONCLUSIONS: Dermatologists should promote COVID-19 to prevent biologics disruption. This article is protected by copyright. All rights reserved.","Dermatol Ther","Bragazzi, Nicola Luigi","Ricco, Matteo","Pacifico, Alessia","Malagoli, Piergiorgio","Kridin, Khalaf","Pigatto, Paolo","Damiani, Giovanni","32415727"],"abstract":["BACKGROUND: SARS-CoV-2 become pandemics and there is still a dearth of data about its the potentially among dermatological patients under biologics. OBJECTIVE: To assess health literacy, disease knowledge, treatment dissatisfaction and biologics attitudes toward COVID-19. METHODS: We performed a cross-sectional, questionnaire-based survey on 98/105 consecutive dermatological patients treated with biologics - 51 suffering from plaque psoriasis, 22 from atopic dermatitis, and 25 from hidradenitis suppurativa. An ad hoc, validated questionnaire has 44 items investigating the following domains: knowledge of COVID-19 related to i) epidemiology, ii) pathogenesis, iii) clinical symptoms, iv) preventive measures and v) attitudes. Patients data and questionnaires were collected. RESULTS: Despite only 8.1% thought that biologics may increase the risk of COVID-19, 18.4% and 21.4% of the patients were evaluating the possibility to discontinue or modify the dosage of the current biologic therapy, respectively. Globally, male patients(p=0.001) with higher scholarity level(p=0.005) displayed higher knowledge of COVID-19. Patients with lower DLQI(p=0.006), longer disease duration(p=0.051) and lower scholarity(p=0.007) have thought to discontinue/modify autonomously their biologic therapy.At the multivariate logistic regression, only the knowledge of epidemiology and preventive measures resulted independent predictors of continuation versus discontinuation and modification versus no modification, respectively. CONCLUSIONS: Dermatologists should promote COVID-19 to prevent biologics disruption. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Bragazzi, Nicola Luigi","Ricco, Matteo","Pacifico, Alessia","Malagoli, Piergiorgio","Kridin, Khalaf","Pigatto, Paolo","Damiani, Giovanni"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32415727","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/dth.13508","keywords":["atopic dermatitis","biologics","covid-19","covid-19 questionnaire","hidradenitis suppurativa","psoriasis","sars-cov-2"],"locations":["Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666991242692526081,"score":9.490897,"similar":[{"pmid":32356577,"title":"Biologics increase the risk of SARS- CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during RED-ZONE declaration.","text":["Biologics increase the risk of SARS- CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during RED-ZONE declaration.","During COVID-19 outbreak there are discordant opinion towards the impact on biologics in psoriatic patients. Thus we performed a single center case-control study in Lombardia, the Italian region with the higher number of COVID-19 confirmed cases. We enrolled 1193 PsO patients treated with biologics and small molecules and we used the entire Lombardia population as controls. Notably, 17 PsO patients COVID-19 confirmed were quarantined at home and 5 hospitalized, no PsO patients were admitted to intensive care unit (ICU) or died. With respect to the general population of Lombardy, patients on biologics were at higher risk to be symptomatic for COVID-19 (OR 3.43 [95%CI 2.25-5.73], P < 0.0001), to be self-quarantined at home (OR 9.05 [95%CI 5.61-14.61], P < 0.0001) and hospitalized (OR 3.59 [95%CI 1.49-8.63], P = 0.0044) however not increased risk of ICU admission or death were found. PsO Patients on biologics should be carefully monitored with telemedicine during COVID-19 outbreak and early treated at home to limit hospital overwhelm. This article is protected by copyright. All rights reserved.","Dermatol Ther","Damiani, Giovanni","Pacifico, Alessia","Bragazzi, Nicola L","Malagoli, Piergiorgio","32356577"],"abstract":["During COVID-19 outbreak there are discordant opinion towards the impact on biologics in psoriatic patients. Thus we performed a single center case-control study in Lombardia, the Italian region with the higher number of COVID-19 confirmed cases. We enrolled 1193 PsO patients treated with biologics and small molecules and we used the entire Lombardia population as controls. Notably, 17 PsO patients COVID-19 confirmed were quarantined at home and 5 hospitalized, no PsO patients were admitted to intensive care unit (ICU) or died. With respect to the general population of Lombardy, patients on biologics were at higher risk to be symptomatic for COVID-19 (OR 3.43 [95%CI 2.25-5.73], P < 0.0001), to be self-quarantined at home (OR 9.05 [95%CI 5.61-14.61], P < 0.0001) and hospitalized (OR 3.59 [95%CI 1.49-8.63], P = 0.0044) however not increased risk of ICU admission or death were found. PsO Patients on biologics should be carefully monitored with telemedicine during COVID-19 outbreak and early treated at home to limit hospital overwhelm. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Damiani, Giovanni","Pacifico, Alessia","Bragazzi, Nicola L","Malagoli, Piergiorgio"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32356577","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/dth.13475","keywords":["bilateral interstitial pneumonia","biologics","covid-19","pandemic","psoriasis","psoriatic arthritis","sars-cov-2"],"locations":["Lombardia","Italian","Lombardy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666138495229362176,"score":394.02917},{"pmid":32458536,"title":"Considerations for Safety in the Use of Systemic Medications for Psoriasis and Atopic Dermatitis during the COVID-19 pandemic.","text":["Considerations for Safety in the Use of Systemic Medications for Psoriasis and Atopic Dermatitis during the COVID-19 pandemic.","Coronavirus disease 2019 (COVID-19), is responsible for at least 2,546,527 cases and 175,812 deaths as of April 21, 2020. Psoriasis and atopic dermatitis are common, chronic, inflammatory skin conditions, with immune dysregulation as a shared mechanism; therefore, mainstays of treatment include systemic immunomodulating therapies. It is unknown whether these therapies are associated with increased to COVID-19 susceptibility or worse outcomes in infected patients. In this review, we discuss overall infection risks of non-biologic and biologic systemic medications for psoriasis and atopic dermatitis, and provide therapeutic recommendations. In summary, in patients with active infection, systemic conventional medications, the JAK inhibitor tofacitinib, and biologics for psoriasis should be temporarily held until there is more data; in uninfected patients switching to safer alternatives should be considered. Interleukin (IL)-17, IL-12/23 and IL-23 inhibitors are associated with low infection risk, with IL-17 and IL-23 favored over IL-12/23 inhibitors. Pivotal trials and postmarketing data also suggest that IL-17 and IL-23 blockers are safer than TNF-blockers. Apremilast, acitretin and dupilumab, have favorable safety data, and may be safely initiated and continued in uninfected patients. Without definitive COVID-19 data, these recommendations may be useful in guiding treatment of psoriasis and atopic dermatitis patients during the COVID-19 pandemic. This article is protected by copyright. All rights reserved.","Dermatol Ther","Ricardo, Jose W","Lipner, Shari R","32458536"],"abstract":["Coronavirus disease 2019 (COVID-19), is responsible for at least 2,546,527 cases and 175,812 deaths as of April 21, 2020. Psoriasis and atopic dermatitis are common, chronic, inflammatory skin conditions, with immune dysregulation as a shared mechanism; therefore, mainstays of treatment include systemic immunomodulating therapies. It is unknown whether these therapies are associated with increased to COVID-19 susceptibility or worse outcomes in infected patients. In this review, we discuss overall infection risks of non-biologic and biologic systemic medications for psoriasis and atopic dermatitis, and provide therapeutic recommendations. In summary, in patients with active infection, systemic conventional medications, the JAK inhibitor tofacitinib, and biologics for psoriasis should be temporarily held until there is more data; in uninfected patients switching to safer alternatives should be considered. Interleukin (IL)-17, IL-12/23 and IL-23 inhibitors are associated with low infection risk, with IL-17 and IL-23 favored over IL-12/23 inhibitors. Pivotal trials and postmarketing data also suggest that IL-17 and IL-23 blockers are safer than TNF-blockers. Apremilast, acitretin and dupilumab, have favorable safety data, and may be safely initiated and continued in uninfected patients. Without definitive COVID-19 data, these recommendations may be useful in guiding treatment of psoriasis and atopic dermatitis patients during the COVID-19 pandemic. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Ricardo, Jose W","Lipner, Shari R"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32458536","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/dth.13687","keywords":["covid-19","atopic dermatitis","biologics","immunosuppression","psoriasis"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1667967699005734912,"score":362.82465},{"pmid":32300516,"pmcid":"PMC7160052","title":"Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.","text":["Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.","With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or more severe disease course. This commentary offers patient counseling recommendations based on the current available evidence. While there are currently no specific data for psoriasis biologics and COVID-19, data are presented here from phase III clinical trials of psoriasis biologics on rates of upper respiratory infection, influenza, and serious infection. Overall these data reveal that on the whole, psoriasis biologics do not show major increases in infection risk compared to placebo during the course of these trials. However, as the COVID-19 virus is a novel pathogen that is associated with mortality in a subset of patients, a cautious approach is warranted. We discuss factors that may alter the benefit-risk ratio of biologic use during this time of COVID-19 outbreak. Ultimately, treatment decisions should be made on the basis of dialogue between patient and provider, considering each patient's individualized situation. Once this pandemic has passed, it is only a matter of time before a new viral disease reignites the same issues discussed here.","Dermatol Ther (Heidelb)","Brownstone, Nicholas D","Thibodeaux, Quinn G","Reddy, Vidhatha D","Myers, Bridget A","Chan, Stephanie Y","Bhutani, Tina","Liao, Wilson","32300516"],"abstract":["With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or more severe disease course. This commentary offers patient counseling recommendations based on the current available evidence. While there are currently no specific data for psoriasis biologics and COVID-19, data are presented here from phase III clinical trials of psoriasis biologics on rates of upper respiratory infection, influenza, and serious infection. Overall these data reveal that on the whole, psoriasis biologics do not show major increases in infection risk compared to placebo during the course of these trials. However, as the COVID-19 virus is a novel pathogen that is associated with mortality in a subset of patients, a cautious approach is warranted. We discuss factors that may alter the benefit-risk ratio of biologic use during this time of COVID-19 outbreak. Ultimately, treatment decisions should be made on the basis of dialogue between patient and provider, considering each patient's individualized situation. Once this pandemic has passed, it is only a matter of time before a new viral disease reignites the same issues discussed here."],"journal":"Dermatol Ther (Heidelb)","authors":["Brownstone, Nicholas D","Thibodeaux, Quinn G","Reddy, Vidhatha D","Myers, Bridget A","Chan, Stephanie Y","Bhutani, Tina","Liao, Wilson"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32300516","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s13555-020-00377-9","keywords":["biologics","covid-19","coronavirus","infection","pandemic","psoriasis","sars-cov-2"],"topics":["Treatment"],"weight":1,"_version_":1666138494813077506,"score":323.6634},{"pmid":32500526,"title":"Considerations on Biologicals for Patients with allergic disease in times of the COVID-19 pandemic: an EAACI Statement.","text":["Considerations on Biologicals for Patients with allergic disease in times of the COVID-19 pandemic: an EAACI Statement.","The outbreak of the SARS-CoV-2-induced Coronavirus Disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex patients with severe allergic disease. A significant numberof the patients are on treatment with biologicals and clinicians face the challenge to provide optimal care during the pandemic. Uncertainty of the potential risks for these patients is related to the fact that the exact sequence of immunological events during SARS-CoV-2 is not known. Severe COVID-19 patients may experience a \"cytokine storm\" and associated organ damage characterized by an exaggerated release of proinflammatory type 1 and type 3 cytokines. These inflammatory responses are potentially counteracted by anti-inflammatory cytokines and type 2 responses. This expert based EAACI statement aims to provide guidance on the application of biologicals targeting type 2 inflammation in patients with allergic disease. Currently, there is very little evidence for an enhanced risk of patients with allergic diseases to develop severe COVID-19 with studies focusing on severe allergic phenotypes lacking. At present, non-infected patients on biologicals for the treatment of asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps or chronic spontaneous urticaria should continue their biologicals targeting type 2 inflammation via self-application. In case of an active SARS-CoV-2 infection, biological treatment needs to be stopped until clinical recovery and SARS-CoV-2 negativity is established and treatment with biologicals should be re-initiated. Maintenance of add-on therapy and a constant assessment of disease control, apart from acute management is demanded.","Allergy","Vultaggio, Alessandra","Agache, Ioana","Akdis, Cezmi A","Akdis, Mubeccel","Bavbek, Sevim","Bossios, Apostolos","Bousquet, Jean","Boyman, Onur","Chaker, Adam M","Chan, Susan","Chatzipetrou, Alexia","Feleszko, Wojciech","Firinu, Davide","Jutel, Marek","Kauppi, Paula","Klimek, Ludger","Kolios, Antonios","Kothari, Akash","Kowalski, Marek L","Matucci, Andrea","Palomares, Oscar","Pfaar, Oliver","Rogala, Barbara","Untersmayr, Eva","Eiwegger, Thomas","32500526"],"abstract":["The outbreak of the SARS-CoV-2-induced Coronavirus Disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex patients with severe allergic disease. A significant numberof the patients are on treatment with biologicals and clinicians face the challenge to provide optimal care during the pandemic. Uncertainty of the potential risks for these patients is related to the fact that the exact sequence of immunological events during SARS-CoV-2 is not known. Severe COVID-19 patients may experience a \"cytokine storm\" and associated organ damage characterized by an exaggerated release of proinflammatory type 1 and type 3 cytokines. These inflammatory responses are potentially counteracted by anti-inflammatory cytokines and type 2 responses. This expert based EAACI statement aims to provide guidance on the application of biologicals targeting type 2 inflammation in patients with allergic disease. Currently, there is very little evidence for an enhanced risk of patients with allergic diseases to develop severe COVID-19 with studies focusing on severe allergic phenotypes lacking. At present, non-infected patients on biologicals for the treatment of asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps or chronic spontaneous urticaria should continue their biologicals targeting type 2 inflammation via self-application. In case of an active SARS-CoV-2 infection, biological treatment needs to be stopped until clinical recovery and SARS-CoV-2 negativity is established and treatment with biologicals should be re-initiated. Maintenance of add-on therapy and a constant assessment of disease control, apart from acute management is demanded."],"journal":"Allergy","authors":["Vultaggio, Alessandra","Agache, Ioana","Akdis, Cezmi A","Akdis, Mubeccel","Bavbek, Sevim","Bossios, Apostolos","Bousquet, Jean","Boyman, Onur","Chaker, Adam M","Chan, Susan","Chatzipetrou, Alexia","Feleszko, Wojciech","Firinu, Davide","Jutel, Marek","Kauppi, Paula","Klimek, Ludger","Kolios, Antonios","Kothari, Akash","Kowalski, Marek L","Matucci, Andrea","Palomares, Oscar","Pfaar, Oliver","Rogala, Barbara","Untersmayr, Eva","Eiwegger, Thomas"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32500526","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/all.14407","topics":["Prevention"],"weight":1,"_version_":1668890966306586624,"score":284.99664},{"pmid":32468230,"pmcid":"PMC7255969","title":"Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).","text":["Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).","The outbreak of the novel coronavirus known as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) causing COVID-19 was first reported in late December 2019. Many patients with psoriasis on biologic therapy have asked their medical providers about the effect of biologics on COVID-19. However, it is currently unknown how biologic therapy for psoriasis might impact patients with psoriasis and COVID-19. In this article, we report on the clinical course of two patients on biologic medication for psoriasis who developed COVID-19 and successfully recovered from SARS-CoV-2 infection. Both patients presented with fever and respiratory symptoms, but neither patient required hospitalization. While more research is needed, it is reassuring to know that successful recovery is possible after COVID-19 infection in patients on biologic therapy for psoriasis.","Dermatol Ther (Heidelb)","Brownstone, Nicholas D","Thibodeaux, Quinn G","Reddy, Vidhatha D","Myers, Bridget A","Chan, Stephanie Y","Bhutani, Tina","Liao, Wilson","32468230"],"abstract":["The outbreak of the novel coronavirus known as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) causing COVID-19 was first reported in late December 2019. Many patients with psoriasis on biologic therapy have asked their medical providers about the effect of biologics on COVID-19. However, it is currently unknown how biologic therapy for psoriasis might impact patients with psoriasis and COVID-19. In this article, we report on the clinical course of two patients on biologic medication for psoriasis who developed COVID-19 and successfully recovered from SARS-CoV-2 infection. Both patients presented with fever and respiratory symptoms, but neither patient required hospitalization. While more research is needed, it is reassuring to know that successful recovery is possible after COVID-19 infection in patients on biologic therapy for psoriasis."],"journal":"Dermatol Ther (Heidelb)","authors":["Brownstone, Nicholas D","Thibodeaux, Quinn G","Reddy, Vidhatha D","Myers, Bridget A","Chan, Stephanie Y","Bhutani, Tina","Liao, Wilson"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32468230","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s13555-020-00394-8","keywords":["biologics","covid-19","infection","pandemic","psoriasis","sars-cov-2","virus"],"topics":["Case Report"],"weight":1,"_version_":1668420887157669888,"score":278.9569}]}